EUVIMEDEUVIMED entdecken
ValidierungsstudieBeobachtungsstudieRandomisierte kontrollierte Studie

External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based Therapy

Xingmei Liao, Qing Xie, Xiaoguang Dou, Junqi Niu, Hong Ma, Yali Liu, Shumei Lin, Huiying Rao, Song Yang, Jianping Xie, Mingxiang Zhang, Qiang Li und 11 weitere

Clinical Gastroenterology and Hepatology · 2026-03 · 24 (3) · 743-753.e9

DOI: 10.1016/j.cgh.2025.06.005 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Xingmei Liao und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory for Preventio…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Interferon-alpha, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: GOLDEN model is designed to predict hepatitis B surface antigen (HBsAg) loss based on patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogues therapy. We aimed to validate GOLDEN model's effectiveness in predicting HBsAg loss or decline in interferon-α-treated patients with CHB. METHODS: Interferon-α-treated patients were enrolled from EXCEL study, a randomized controlled trial that included hepatitis B e antigen-positive, noncirrhotic, treatment-naive patients with CHB, and Search-B cohort, a prospective real-world observational cohort of CHB. Using multiple quantitative HBsAg (qHBsAg) measurements, GOLDEN model was used to calculate a patient's probability of achieving HBsAg loss or decline. RESULTS: Among 200 patients in the EXCEL study and 1041 patients from the Search-B cohort, the corresponding cumulative incidence of qHBsAg

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B Surface AntigensInterferon-alphaAntiviral AgentsHumansMaleFemaleAdultMiddle AgedProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

Chronic Hepatitis BFunctional CureGOLDEN ModelInterferon-AlphaQuantitative Hepatitis B Surface Antigen

Substanzen

Hepatitis B Surface AntigensInterferon-alphaAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China; Guangdong Pro…
  • Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Liver, First Hospital of Jilin University, Changchun, China.
  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Beijing Youan Hospital, Capital Medical University, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Liao, X., Xie, Q., Dou, X., Niu, J., Ma, H., Liu, Y., Lin, S., Rao, H., Yang, S., Xie, J., Zhang, M., Li, Q., Yu, Y., Ning, Q., Li, W., Li, C., Zhang, L., Zhang, Z., Han, T., …, & Chronic Hepatitis B Study Consortium (2026). External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based Therapy. Clinical Gastroenterology and Hepatology, 24(3), 743-753.e9. https://doi.org/10.1016/j.cgh.2025.06.005

Vancouver

Liao X, Xie Q, Dou X, Niu J, Ma H, Liu Y, et al. External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based Therapy. Clinical Gastroenterology and Hepatology. 2026;24(3):743-753.e9. doi:10.1016/j.cgh.2025.06.005

BibTeX
@article{Liao2026,
  author = {Liao, Xingmei and Xie, Qing and Dou, Xiaoguang and Niu, Junqi and Ma, Hong and Liu, Yali and Lin, Shumei and Rao, Huiying and Yang, Song and Xie, Jianping and Zhang, Mingxiang and Li, Qiang and Yu, Yanyan and Ning, Qin and Li, Wu and Li, Chengzhong and Zhang, Liaoyun and Zhang, Zhengang and Han, Tao and Sun, Jian and Hou, Jinlin and Fan, Rong and Chronic Hepatitis B Study Consortium, Chronic Hepatitis B Study Consortium},
  title = {External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based Therapy},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {743--753.e9},
  doi = {10.1016/j.cgh.2025.06.005}
}
Kostenlos starten →